0001209191-20-051048.txt : 20200917
0001209191-20-051048.hdr.sgml : 20200917
20200917192001
ACCESSION NUMBER: 0001209191-20-051048
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200717
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THURMAN RANDY H
CENTRAL INDEX KEY: 0001204059
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 201182338
MAIL ADDRESS:
STREET 1: 222 MERCHANDISE MART PLAZA
STREET 2: SUITE 2024
CITY: CHICAGO
STATE: IL
ZIP: 60654
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-07-17
2020-07-21
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001204059
THURMAN RANDY H
C/O OUTLOOK THERAPEUTICS, INC.
4260 US ROUTE 1
MONMOUTH JUNCTION
NJ
08852
1
0
0
0
Stock Option (Right to Buy)
1.58
2020-07-17
4
A
0
154555
0.00
A
2030-07-17
Common Stock
154555
154555
D
The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.
This Form 4/A is being filed to reflect the correct number of shares underlying the option granted to the Reporting Person on July 17, 2020 to 154,555 shares instead of the 210,000 shares reported in the Form 4 filed with the Securities and Exchange Commission on July 21, 2020.
/s/ Lawrence Kenyon, Attorney-in-Fact
2020-09-17